Skip to content

Study · Not a test of the peptide alone · 1986

5 results

Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D.

Slovik DM, Rosenthal DI, Doppelt SH, Potts JT Jr, Daly MA, Campbell JA, Neer RM

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Aug 1986Cited by 189 (Europe PMC)

PMID3503551 (opens in a new tab)DOI10.1002/jbmr.5650010411 (opens in a new tab)PepBankPUB-03503551
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 01HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In men with idiopathic osteoporosis, PTH plus active vitamin D increased spinal trabecular bone density during treatment.

    In plain wordsIn men with osteoporosis, PTH plus active vitamin D increased spinal bone density during treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSpinal trabecular bone density
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Daily subcutaneous injection of a synthetic human parathyroid hormone fragment, combined with daily ingestion of 1,25(OH)2 vitamin D, significantly increased trabecular bone density in the spine (p less than .01)
    1 context sentence
    Summary · context
    The increases in spinal bone mineral were marked and progressive during a year of treatment.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 02HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In men with idiopathic osteoporosis, PTH plus active vitamin D improved intestinal calcium absorption.

    In plain wordsIn men with osteoporosis, PTH plus active vitamin D improved intestinal calcium absorption during treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseIntestinal calcium absorption
    Study

    n: not reported in source

    Outcome group
    Intestinal growth and absorption · Gastrointestinal

    Source sentences

    Summary
    and improved intestinal calcium and phosphorus absorption and total body retention of dietary calcium and phosphorus in middle-aged men with idiopathic osteoporosis.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 03HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In men with idiopathic osteoporosis, PTH plus active vitamin D improved intestinal phosphorus absorption.

    In plain wordsIn men with osteoporosis, PTH plus active vitamin D improved intestinal phosphorus absorption during treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseIntestinal phosphorus absorption
    Study

    n: not reported in source

    Outcome group
    Intestinal growth and absorption · Gastrointestinal

    Source sentences

    Summary
    and improved intestinal calcium and phosphorus absorption and total body retention of dietary calcium and phosphorus in middle-aged men with idiopathic osteoporosis.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 04HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In men with idiopathic osteoporosis, PTH plus active vitamin D improved total body retention of dietary calcium.

    In plain wordsIn men with osteoporosis, PTH plus active vitamin D improved dietary calcium retention during treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseDietary calcium retention
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    and improved intestinal calcium and phosphorus absorption and total body retention of dietary calcium and phosphorus in middle-aged men with idiopathic osteoporosis.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  5. 05HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In men with idiopathic osteoporosis, PTH plus active vitamin D improved total body retention of dietary phosphorus.

    In plain wordsIn men with osteoporosis, PTH plus active vitamin D improved dietary phosphorus retention during treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseDietary phosphorus retention
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    and improved intestinal calcium and phosphorus absorption and total body retention of dietary calcium and phosphorus in middle-aged men with idiopathic osteoporosis.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.